Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1α, tumor necrosis factor-α, transforming growth factor-β and oncostatin M in human cardiac myocytes

被引:63
作者
Macfelda, K
Weiss, TW
Kaun, C
Breuss, JM
Kapeller, B
Zorn, G
Oberndorfer, U
Voegele-Kadletz, M
Huber-Beckmann, R
Ullrich, R
Binder, BR
Losert, UM
Maurer, G
Pacher, R
Huber, K
Wojta, J
机构
[1] Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria
[2] Univ Vienna, Inst Biomed Res, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria
[4] Univ Vienna, Dept Cardiothorac Surg, A-1090 Vienna, Austria
[5] Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria
关键词
PAI-1; cardiac myocytes; inflammatory mediators; cardiac repair;
D O I
10.1006/jmcc.2002.2117
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen Activator Inhibitor 1 Expression is Regulated by the Inflammatory Mediators Interleukin-la, Tumor Necrosis Factor-a, Transforming Growth Factor-beta and Oncostatin M in Human Cardiac Myocytes. Journal of Molecular and Cellular Cardiology (2002) 34, 1681-1691. Accumulating evidence points towards a role for proteases and protease inhibitors in tissue remodelling and repair in a variety of organs. In particular-besides the matrix metalloprotease system-the plasminogen activator (PA)/plasmin system has been implicated in these processes in the heart. Urokinase type PA (u-PA) and PA inhibitor type 1 (PAI-1) seem to modulate cardiac rupture and infarct healing. In this study we aimed to investigate whether inflammatory mediators can regulate the expression of components of the PA/plasmin system in human adult cardiac myocytes (HACM). We could demonstrate that HACK isolated from pieces of myocardial tissue by mechanical dispersion and characterized by positive immunostaining for the cardiac markers troponin 1, tropomyosin, cardiotin and myocardial muscle-actin, in vitro express PAI-1 and tissue type PA (t-PA) whereas u-PA was not detectable in these cells. PAT-1 protein production was increased up to twofold by interleukin-lalpha (IL-1alpha) and tumor necrosis factor-alpha (TNF-alpha) and up to fivefold by transforming growth factor-beta (TGF-beta) and oncostatin M (OSM). Similar changes were observed in PAI-1 transcript levels after cytokine treatment. t-PA production in HACM was not affected by these agonists. No effect of these cytokines on PAI-1 production in fibroblasts isolated from human myocardial tissue was seen. In an ex vivo model we could show that incubation of pieces of human myocardial tissue with these cytokines also resulted in an increase in PAI-1 in cardiac myocytes as evidenced by immuno-histochemistry. Furthermore we found increased PAI-1 expression in myocardial tissue from a patient suffering from acute myocarditis. Thus for the first time we provide evidence that inflammatory mediators modulate PAI-1 expression in human adult cardiac myocytes in vitro and ex vivo and could demonstrate that PAI-1 expression is increased in the in vivo setting under inflammatory conditions. If the effect on PAI-1 expression brought about by IL-1alpha, TNF-alpha, TGF-beta and OSM is not only operative under in vitro and ex vivo conditions but also in the in vivo setting one could speculate that these cytokines contribute to upregulation of PAI-1 in myocardial tissue and that PAI-1, when upregulated in myocardial tissue during inflammatory processes, could serve as a defence mechanism against excessive matrix degradation by proteases. Thus we propose a role for PAI-1 produced in the heart by cardiac myocytes in cardiac remodelling and repair processes. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1681 / 1691
页数:11
相关论文
共 39 条
[11]   THROMBIN INDUCTION OF PLASMINOGEN ACTIVATOR-INHIBITOR IN CULTURED HUMAN-ENDOTHELIAL CELLS [J].
GELEHRTER, TD ;
SZNYCERLASZUK, R .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (01) :165-169
[12]   Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice [J].
Glück, B ;
Schmidtke, M ;
Merkle, I ;
Stelzner, A ;
Gemsa, D .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (09) :1615-1626
[13]   Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure [J].
Heymans, S ;
Luttun, A ;
Nuyens, D ;
Theilmeier, G ;
Creemers, E ;
Moons, L ;
Dyspersin, GD ;
Cleutjens, JPM ;
Shipley, M ;
Angellilo, A ;
Levi, M ;
Nübe, O ;
Baker, A ;
Keshet, E ;
Lupu, F ;
Herbert, JM ;
Smits, JFM ;
Shapiro, SD ;
Baes, M ;
Borgers, M ;
Collen, D ;
Daemen, MJAP ;
Carmeliet, P .
NATURE MEDICINE, 1999, 5 (10) :1135-1142
[14]   UROKINASE PLASMINOGEN-ACTIVATOR ACTIVITY IS INCREASED IN THE MYOCARDIUM DURING CORONARY-ARTERY OCCLUSION [J].
KNOEPFLER, PS ;
BLOOR, CM ;
CARROLL, SM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1995, 27 (06) :1317-1324
[15]   ENHANCED PRODUCTION AND EXTRACELLULAR DEPOSITION OF THE ENDOTHELIAL-TYPE PLASMINOGEN-ACTIVATOR INHIBITOR IN CULTURED HUMAN-LUNG FIBROBLASTS BY TRANSFORMING GROWTH-FACTOR-BETA [J].
LAIHO, M ;
SAKSELA, O ;
ANDREASEN, PA ;
KESKIOJA, J .
JOURNAL OF CELL BIOLOGY, 1986, 103 (06) :2403-2410
[16]   Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells [J].
Li, YY ;
McTiernan, CF ;
Feldman, AM .
CARDIOVASCULAR RESEARCH, 1999, 42 (01) :162-172
[17]   Differential expression of tissue inhibitors of metalloproteinases in the failing human heart [J].
Li, YY ;
Feldman, AM ;
Sun, Y ;
McTiernan, CF .
CIRCULATION, 1998, 98 (17) :1728-1734
[18]  
LUCORE CL, 1988, J BIOL CHEM, V263, P15845
[19]   SUPPRESSION OF PLASMINOGEN-ACTIVATOR ACTIVITY BY DEXAMETHASONE IN CULTURED CARDIAC MYOCYTES [J].
MAYER, M ;
FINCI, Z ;
CHAOUAT, M .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1986, 18 (11) :1117-1124
[20]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INHIBITOR-2 ARE TUMOR NECROSIS FACTOR CACHECTIN-RESPONSIVE GENES [J].
MEDCALF, RL ;
KRUITHOF, EKO ;
SCHLEUNING, WD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (02) :751-759